WO2010101213A1 - 検査試薬及びそれを用いた被検試料中の被測定物の測定方法 - Google Patents
検査試薬及びそれを用いた被検試料中の被測定物の測定方法 Download PDFInfo
- Publication number
- WO2010101213A1 WO2010101213A1 PCT/JP2010/053541 JP2010053541W WO2010101213A1 WO 2010101213 A1 WO2010101213 A1 WO 2010101213A1 JP 2010053541 W JP2010053541 W JP 2010053541W WO 2010101213 A1 WO2010101213 A1 WO 2010101213A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liquid
- test
- solution
- particles
- test sample
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
Definitions
- the present invention relates to a test reagent for a test object in a test sample, which uses as an index the aggregation of particles in a particle suspension in which particles supported on insoluble carrier particles are suspended.
- the present invention relates to a method for measuring the object to be measured.
- the measurement object in the test sample using the degree of particle aggregation as an index is known as an immunoagglutination method and is widely used.
- An insoluble carrier carrying a protein suspended in a solvent having a low ionic strength with a NaCl concentration of not more than a certain concentration, that is, a low electrical conductivity, is excellent in efficiently obtaining dispersibility and sensitivity.
- nonspecific aggregation may occur due to contamination of ions from contaminants in the biological material.
- an interfering substance that affects the immune reaction of a target substance exists in a biological sample.
- methods using reagents using various additives are widely used.
- a method is known that uses a reaction solution for detecting a target substance and a buffer solution that is a second reagent in which a substance capable of avoiding the influence of an interfering substance coexists.
- a buffer solution a solution having an electric conductivity close to that of physiological saline (about 15 to 20 ms / cm) is often used.
- nonspecific aggregation may occur only by mixing the reaction solution and the buffer during measurement.
- additives eg, polyethylene glycol, guanidine
- the electrical conductivity increases, and non-specific aggregation may occur only by mixing the reagent solution and the buffer solution at the time of measurement.
- An object of the present invention is to provide a test reagent for a test object in a test sample, which uses as an index the aggregation of particles in a particle suspension in which particles supported on insoluble carrier particles are suspended.
- An object of the present invention is to provide a test reagent in which self-aggregation does not occur during storage and non-specific aggregation hardly occurs during measurement, and a method for measuring an analyte in a test sample using the same. .
- the inventors of the present application have made the test reagent a two-liquid system containing a particle suspension and a buffer separately, and lowering the electric conductivity of the particle suspension below a specific value,
- the electrical conductivity is higher than a specific value, which is higher than the electrical conductivity of the buffer that is usually used as a test reagent, and measurement is performed by mixing the buffer and the particle suspension immediately before starting the measurement operation.
- the present invention is a solution A, which is a buffer solution having an electric conductivity of 30 ms / cm or more, and a particle suspension in which particles on which an analyte capturing substance is supported are suspended on insoluble carrier particles.
- a test reagent for measuring the object to be measured comprising at least a liquid B having an electric conductivity of 6.5 ⁇ ms / cm or less.
- the present invention also relates to a method for measuring an object to be measured in a test sample using the test reagent of the present invention, wherein the liquid A, the liquid B, and the test sample are mixed. And measuring the degree of aggregation of the particles in the obtained mixed liquid, and at least the liquid A and the liquid B are mixed immediately before the start of the measurement operation, A method for measuring a measurement object is provided.
- self-aggregation does not occur during storage of the reagent, and non-specific aggregation hardly occurs at the time of measurement, so that the measurement object in the test sample can be accurately measured.
- the reagent of the present invention includes a solution A that is a buffer solution and a solution B that is a particle suspension.
- a liquid and B liquid are separate liquids accommodated in separate containers, and are mixed immediately before the start of the measurement operation. The mode of mixing will be described later.
- the buffer contained in solution A which is a buffer, may be a well-known buffer that is usually used as a test reagent.
- the electric conductivity of the liquid A is 30 ms / cm or more, preferably 35 ms / cm or more.
- the upper limit of the electric conductivity is not particularly limited, but usually the electric conductivity is 200 ms / cm or less, preferably 100 ms / cm or less.
- the electrical conductivity of the liquid A is 30 ms / cm or more, nonspecific aggregation during measurement is remarkably suppressed.
- a buffer solution widely used in a test reagent one having an electric conductivity comparable to that of physiological saline, that is, an electric conductivity of about 15 to 20 ms / cm is used. Therefore, one feature of the present invention is to use a buffer having a higher electrical conductivity than usual.
- the electrical conductivity can be measured by a conventional method using a commercially available electrical conductivity meter. The electrical conductivity is measured at room temperature.
- the electrical conductivity of the liquid A can be adjusted to an arbitrary value by adjusting the concentration of the above-mentioned buffer or adding a water-soluble ionic compound.
- water-soluble ionic compounds that can be used include chlorides, bromides, iodides, carbonates, bicarbonates, acetates, and sulfates of alkali metals such as sodium and potassium and alkaline earth metals such as magnesium and calcium. Examples include salt and alums. Of these, NaCl is simple and preferred. If a commercially available electric conductivity meter is used, the electric conductivity of the liquid can be measured in real time. Therefore, the desired electric conductivity can be easily obtained by adding a water-soluble ionic compound while measuring the electric conductivity. Can be achieved.
- the liquid B contains particles in which the analyte capturing substance is supported on the insoluble carrier particles in a floating state.
- This suspended particle is not limited at all, and may be a well-known particle conventionally used in a test reagent.
- the analyte capture substance may be any substance that can specifically bind to the analyte to be measured, and can bind to the analyte by a specific binding reaction such as an antigen-antibody reaction or a ligand-receptor reaction.
- a method using an antigen-antibody reaction is a well-known immunoassay method called an immunoagglutination method, and when an object to be measured is an antigen, an antibody or antigen-binding fragment thereof (antigen-binding fragment of the antigen) reacts with the antigen.
- Fab fragments, F (ab ′) 2 fragments, etc. that maintain binding properties) are carried.
- the object to be measured is an antibody
- the antibody since the antibody is also an antigen, an antibody that undergoes an antigen-antibody reaction with the antibody or an antigen-binding fragment thereof is carried.
- These antibodies may be monoclonal antibodies or polyclonal antibodies.
- the analyte is an antigen
- the analyte is a protein such as CRP (C-reactive protein), prostate specific antigen, ferritin, ⁇ -2 microglobulin, myoglobin, megalin, podocalyxin transferrin, albumin, creatinine, etc.
- Markers various tumor markers, lipoproteins such as LDL, HDL, TG, influenza A virus, influenza B virus, RS virus (RSV), rhinovirus, rotavirus, norovirus, adenovirus, astrovirus, HAV, HBs, Virus antigens such as HCV, HIV, EBV, Chlamydia trachomatis, Streptococcus, Bordetella pertussis, Helicobacter pylori, Leptospira, Treponema pallidum, Toxoplasma gondii, Borrelia, Legionella, Bacillus anthracis, MRSA, etc.
- lipoproteins such as LDL, HDL, TG, influenza A virus, influenza B virus, RS virus (RSV), rhinovirus, rotavirus, norovirus, adenovirus, astrovirus, HAV, HBs, Virus antigens such as HCV, HIV, EBV, Chlamydia trachomatis, Str
- Antigens such as CRP, prostate specific antigen, ferritin and ⁇ -2 microglobulin.
- the analyte is an antibody
- the analyte is the above-mentioned protein marker, various tumor markers, lipoproteins, viral antigens, bacterial antigens, toxins produced by bacteria, peptide hormones, steroids, bioactive amines, vitamins And antibodies that react specifically with antigens such as antibiotics, agricultural chemicals, and environmental hormones.
- the analyte trapping substance that binds to the analyte is sensitized to the carrier particles as an antibody.
- an antigen-sensitizing substance is sensitized to a carrier particle with an object capturing substance that binds to the object to be measured.
- the analyte is a ligand
- the analyte capture substance that binds to the analyte is sensitized to the carrier particles as a receptor
- the analyte capture substance that binds to the analyte is supported by the carrier.
- the particles are used as a ligand.
- the insoluble carrier may be a well-known one that has been conventionally used in a test reagent, and examples thereof include resin latex such as polyethylene and polystyrene, particles such as alumina, silica, colloidal gold, and magnetic particles.
- resin latex such as polyethylene and polystyrene
- particles such as alumina, silica, colloidal gold, and magnetic particles.
- latex particles particularly polystyrene latex particles are preferably used.
- the concentration of suspended particles in the liquid B is appropriately set based on the type of the substance to be measured to be used, the type of the object to be measured, the expected concentration of the object to be measured in the test sample, etc.
- the particle concentration is about 0.01 to 0.5%.
- the electric conductivity of the B liquid is 6.5 ms / cm or less, preferably 5 ms / cm or less.
- the electric conductivity of the liquid B is 6.5 ms / cm or less, preferably 5 ms / cm or less.
- the electric conductivity of the liquid B is 6.5 ms / cm or less, self-aggregation of particles during storage is prevented, and non-specific aggregation during measurement hardly occurs.
- There is no particular lower limit for the electrical conductivity but usually the electrical conductivity is 0.1 ms / cm or more.
- the electric conductivity of 6.5 ms / cm or less is achieved by using, for example, water, alcohol (eg, ethanol, etc.), sugar solution (eg, glucose, sucrose, maltose, lactose, etc.) as the solvent for the B solution.
- Sodium chloride and a buffer may be added to the B liquid within a range where the above electric conductivity is achieved.
- the test reagent of the present invention suppresses coloration reagents and reactive reagents for detecting a test target substance, enzymes such as cholesterol oxidase and cholesterol esterase, surfactants, antibody stabilization and non-specific reactions.
- enzymes such as cholesterol oxidase and cholesterol esterase, surfactants, antibody stabilization and non-specific reactions.
- saccharides for adjusting specific gravity, glycerol, etc. may be used in combination as additives. These additives may be added to the liquid A or the liquid B, and may be added as a reagent (further liquid) different from the liquid A or the liquid B at the time of measurement.
- the measurement method of the present invention using the above-described test reagent of the present invention comprises the steps of mixing the A liquid, the B liquid, and the test sample, and the degree of aggregation of the particles in the obtained mixed liquid. Measuring.
- test sample is not limited in any way as long as it may contain the above-described test target antigen or antibody.
- test sample collected from the human body or animal, preferably from the human body. It is most effective in cases.
- test samples include blood, serum, urine, cerebrospinal fluid, sweat, lymph fluid, saliva, gastric juice and other liquids, feces, hair, keratin, nails, etc., blood, serum, plasma, urine, Cerebrospinal fluid or feces, in particular blood derived from blood, serum, or plasma is preferably used.
- the order of mixing liquid A, liquid B, and test sample is not limited as long as these three parties (additional additives when the test reagent includes separate additives) can be mixed.
- the method of mixing simultaneously, the method of mixing a test sample after mixing A liquid and B liquid, the method of mixing A liquid and a test sample, and mixing with B liquid etc. are mentioned. Aggregation methods using an automatic measuring apparatus are also widely performed, and a commercially available automatic measuring apparatus can also be preferably used in the present invention.
- examples of the mixing of the liquid A, the liquid B, and the test sample include those shown in FIGS. In the method of FIG. 1, the lower liquid is added first, and the upper liquid is added later. The method shown in FIG.
- the method shown in FIG. 3 is a mixing method using a filtration tube.
- the solution A is put in the tube, the test sample is put in a filter, the solution A and the test sample are mixed and filtered, and dropped into the solution B. .
- the “measurement operation” is an operation for measuring the degree of aggregation of particles in the mixed solution, and is usually a measurement of absorbance or turbidity. “Just before” is within 10 minutes, preferably within 5 minutes before the start of the measurement operation.
- the reaction is usually carried out for about 1 minute to 1 hour, preferably about 3 minutes to 15 minutes, as before.
- the degree of aggregation is usually measured by an optical method as in the prior art, and preferably by measuring absorbance or turbidity. Perform measurements on standard samples of various known concentrations, create a calibration curve by plotting the relationship between the concentration and the measured value (absorbance, etc.), and apply the measured value obtained for the test sample to the calibration curve. An object to be measured in a test sample can be measured. Note that “measurement” is used to include detection, quantification, and semi-quantification.
- Test Reagent Kit The test reagent kit of the present invention using the above-described test reagent of the present invention comprises chemicals and parts necessary for the test, such as A liquid, B liquid, and a container.
- Solution A Sodium chloride was added to a buffer containing 100 mM Tris while monitoring the electrical conductivity to obtain a predetermined electrical conductivity. Electrical conductivity 8 ms / cm (sodium chloride concentration 50 mM, Comparative Examples 1 and 5), 16 ms / cm (sodium chloride concentration 150 mM, Comparative Example 2), 35 ms / cm (sodium chloride concentration 400 mM, Example 1), 75 ms / cm (Sodium chloride concentration 1000 mM, Example 2, Comparative Examples 3 and 4), 200 ms / cm (sodium chloride concentration 5000 mM, Example 3).
- Solution B Sodium chloride was added to a reaction solution in which 0.1% of polystyrene latex having an average particle size of 220 nm carrying 0.25 mg / mL of a commercially available anti-CRP antibody was dispersed in water, and a predetermined electric conductivity was obtained. did. Electrical conductivity 5 ms / cm (sodium chloride: 50 mM, Examples 1 to 3, Comparative Examples 1 and 2), 15 ms / cm (sodium chloride: 150 mM, Comparative Example 3), 78 ms / cm (sodium chloride: 1000 mM, Comparative Example) 4, 5).
- Physiological saline was used as a blank test sample, and the reagent obtained by mixing the liquid A and the liquid B was measured with an automatic analyzer to confirm nonspecific aggregation of the reagent. That is, on Hitachi 7180 type (trade name) automatic analyzer, 120 ⁇ L of the above solution A was added to 2.4 ⁇ L of physiological saline, the mixture was stirred and mixed at 37 ° C., allowed to stand for 5 minutes, and then the above B 120 ⁇ L of the solution was added, and further stirred and mixed at 37 ° C. The aggregation reaction for about 5 minutes was measured as the amount of change in absorbance at 570 nm.
- the measurement of CRP was carried out using a solution containing 0.05 mg / dL of CRP as a test sample, and measuring the reagent mixed with the above liquid A and liquid B with an automatic analyzer to confirm the amount of change in absorbance. That is, on a Hitachi 7180 type (trade name) automatic analyzer, 120 ⁇ L of the above solution A was added to 2.4 ⁇ L of CRP 0.05 mg / dL solution, and this mixture was stirred and mixed at 37 ° C. and then left for 5 minutes. 120 ⁇ L of the solution B was added, and the mixture was further stirred and mixed at 37 ° C. The aggregation reaction for about 5 minutes was measured as the amount of change in absorbance at 570 nm.
- Non-specific aggregation at the time of measurement was evaluated according to the following criteria for the amount of change in absorbance at the time of physiological saline measurement using an automatic analyzer.
- the CRP measurement was performed by calculating the difference in absorption change between the blank physiological saline solution and the CRP 0.05 mg / dL solution, and comparing the sensitivity.
- Examples 1 to 3 and Comparative Examples 3 to 5 in which nonspecific aggregation does not occur were compared with respect to the amount of change in absorbance when measuring a CRP 0.05 mg / dL solution.
- Examples 1 to 3 showed higher absorbance change than Comparative Examples 3 to 5.
- Example 2 and Comparative Example 5 the electrical conductivities of the liquid A and the liquid B are set almost opposite to each other, and the final electrical conductivities are almost the same.
- Example 2 in which the electrical conductivity was set lower than that of the A solution showed higher absorbance.
- the test reagent and measurement method including at least the liquid A and the liquid B, which are buffers having electrical conductivity defined in the present invention, can prevent self-aggregation of the latex particles of the liquid B, and are excellent in storage stability. It was. Moreover, non-specific aggregation was prevented and highly sensitive measurement was realized.
- Example 3 Calibration Curve Preparation Using the reagent of Example 2 above, measurement was performed in the same manner as described above using standard solutions containing various concentrations of CRP, and calibration was performed.
- FIG. 4 shows the relationship between the obtained change in absorbance and the CRP concentration.
- Example 4 Measurement of Serum Sample Using the reagent of Example 2 above, CRP was measured in the same manner as above for the serum sample. The measurement was repeated 20 times and the reproducibility was examined. The results are shown in Table 2.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
緩衝液であるA液に含まれる緩衝剤は、検査試薬に通常用いられている周知の緩衝剤であってよく、例えばアラニン、アルギニン、アスパラギン、アスパラギン酸、システイン、グルタミン、グルタミン酸、グリシン、ヒスチジン、イソロイシン、ロイシン、リシン、メチオニン、フェニルアラニン、プロリン、セリン、スレオニン、トリプトファン、チロシン、バリン等のアミノ酸;クエン酸、マレイン酸、グルタル酸等のカルボン酸塩;リン酸ナトリウム、リン酸水素ナトリウム等のリン酸塩;炭酸カルシウム、炭酸マグネシウム等の炭酸塩;グッドの緩衝剤等が好ましく使用可能であり、トリス緩衝剤、グッド緩衝剤、リン酸系緩衝剤が好適に用いられるが、緩衝剤はこれらに限定されるものではない。
上記の通り、B液中には、被測定物捕捉物質が不溶性担体粒子上に担持された粒子が浮遊状態で含まれる。この浮遊粒子は、何ら限定されるものではなく、従来から検査試薬において用いられている周知の粒子であってよい。
上記本発明の検査試薬を用いた本発明の測定方法は、A液と、B液と、被検試料とを混合する工程と、得られた混合液中の前記粒子の凝集の程度を測定する工程とを含む。
上記本発明の検査試薬を用いた本発明の検査試薬キットは、A液、B液及び容器等、検査に必要な薬品及び部品からなる。
以下の通り、浮遊されたタンパク質を担持した不溶性担体粒子を含む粒子浮遊液(B液)の自己凝集の違いを測定した。また、生理食塩水をブランク検体とし、緩衝液(A液)の電気伝導度を変えた反応条件下での非特異的凝集の違いを評価した。また、CRPの測定により感度の違いを評価した。
A液:100mMトリス含有の緩衝液に、電気伝導度をモニターしながら塩化ナトリウムを添加し、所定の電気伝導度とした。電気伝導度8ms/cm(塩化ナトリウム濃度50mM、比較例1、5)、16ms/cm(塩化ナトリウム濃度150mM、比較例2)、35ms/cm(塩化ナトリウム濃度400mM、実施例1)、75ms/cm(塩化ナトリウム濃度1000mM、実施例2、比較例3,4)、200ms/cm(塩化ナトリウム濃度5000mM、実施例3)。
上記のB液の初期の吸光度と1ヵ月後の吸光度を測定して、自己凝集の有無を確認した。
自己凝集は、0.1%ポリスチレンラテックス粒子分散液の吸光度と、B液の吸光度の差を保存の前後でそれぞれ算出し、以下の判定基準に従って各電気伝導度における自己凝集を評価した。
0.1%ポリスチレンラテックス粒子分散液の吸光度を基準として、
○:差が15%以下
×:差が15%超
○:吸光度変化量ΔAbsの10000倍が20以下
×:吸光度変化量ΔAbsの10000倍が20超
CRPの測定は、ブランクである生理食塩液とCRP0.05mg/dL溶液測定時の吸変化量の差を算出し、感度を比較した。
A液及びB液の電気伝導度の測定は、東亜電波工業(株)社製電気伝導率計CM-60G型を用いて行った。
(電極:CT-57101B、温度:25℃)
結果を下記表1に示す。
検量線作成
上記実施例2の試薬を用い、種々の濃度のCRPを含む標準溶液を用いて上記と同様に測定を行い、キャリブレーションを行った。得られた吸光度変化量とCRP濃度の関係を図4に示す。
血清検体の測定
上記実施例2の試薬を用い、血清検体について上記と同様にCRPの測定を行った。測定を20回繰返し行い、その再現性を調べた。結果を表2に示す。
Claims (9)
- 30ms/cm以上の電気伝導度を有する緩衝液であるA液と、被測定物捕捉物質が不溶性担体粒子上に担持された粒子が浮遊している粒子浮遊液であって6.5 ms/cm以下の電気伝導度を有するB液とを少なくとも含む、前記被測定物を測定するための検査試薬。
- 前記A液の電気伝導度が200ms/cm以下である請求項1に記載の検査試薬。
- 前記被測定物捕捉物質が抗体若しくはその抗原結合性断片、又は抗原である請求項1又は2に記載の検査試薬。
- 前記不溶性担体粒子がラテックス粒子である請求項1ないし3のいずれか1項に記載の検査試薬。
- 前記ラテックス粒子がポリスチレンラテックス粒子である請求項4に記載の検査試薬。
- 請求項1ないし5のいずれか1項に記載の検査試薬を用いた、被検試料中の被測定物の測定方法であって、前記A液と、前記B液と、前記被検試料とを混合する工程と、得られた混合液中の前記粒子の凝集の程度を測定する工程とを含み、かつ、少なくとも前記A液と前記B液とは測定操作開始の直前に混合する、被検試料中の被測定物の測定方法。
- 前記被検試料が、尿、髄液、又は糞便である請求項6に記載の測定方法。
- 前記被検試料が血液、血清又は血漿である請求項6に記載の測定方法。
- 請求項1ないし5のいずれか1項に記載の検査試薬を少なくとも含む、検査試薬キット。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011502797A JP5706315B2 (ja) | 2009-03-05 | 2010-03-04 | 検査試薬及びそれを用いた被検試料中の被測定物の測定方法 |
CN201080010075.8A CN102341707B (zh) | 2009-03-05 | 2010-03-04 | 检测试剂以及使用该检测试剂测定检测样品中的被测定物的方法 |
DK10748806.6T DK2418486T3 (da) | 2009-03-05 | 2010-03-04 | Testreagenskit og dets anvendelse i en fremgangsmåde til måling af en analyt i testprøve |
US13/254,765 US9250235B2 (en) | 2009-03-05 | 2010-03-04 | Test reagent, and method for measuring analyte in test sample using same |
EP10748806.6A EP2418486B1 (en) | 2009-03-05 | 2010-03-04 | Test reagent kit and its use in a method for measuring an analyte in test sample |
ES10748806.6T ES2440326T3 (es) | 2009-03-05 | 2010-03-04 | Kit de reactivo de ensayo y uso en un procedimiento para medir un analito en una muestra de ensayo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-051514 | 2009-03-05 | ||
JP2009051514 | 2009-03-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010101213A1 true WO2010101213A1 (ja) | 2010-09-10 |
Family
ID=42709767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/053541 WO2010101213A1 (ja) | 2009-03-05 | 2010-03-04 | 検査試薬及びそれを用いた被検試料中の被測定物の測定方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US9250235B2 (ja) |
EP (1) | EP2418486B1 (ja) |
JP (1) | JP5706315B2 (ja) |
KR (1) | KR101628221B1 (ja) |
CN (1) | CN102341707B (ja) |
DK (1) | DK2418486T3 (ja) |
ES (1) | ES2440326T3 (ja) |
WO (1) | WO2010101213A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013090636A1 (en) * | 2011-12-13 | 2013-06-20 | Baxter International Inc. | Measurement of autoantibodies at low conductivity conditions with increased sensitivity |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6918808B2 (ja) * | 2016-08-31 | 2021-08-11 | 栄研化学株式会社 | 異なる方式で抗原を固定化した抗原担持不溶性担体粒子を用いる抗体測定法、抗体測定用試薬 |
JP6224217B1 (ja) * | 2016-12-27 | 2017-11-01 | Jsr株式会社 | ラテックス粒子分散液の保管方法 |
JP6919499B2 (ja) * | 2017-08-01 | 2021-08-18 | 藤倉化成株式会社 | 不溶性担体粒子を含有する免疫測定試薬の劣化防止手段 |
CN117347617A (zh) * | 2022-06-27 | 2024-01-05 | 菲鹏生物股份有限公司 | 稀释剂及其应用、样品中分析物的测定方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57182168A (en) | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Immunochemical reagent |
JPH06167495A (ja) * | 1992-07-14 | 1994-06-14 | S R L:Kk | 凝集イムノアッセイ法 |
JPH0720129A (ja) * | 1993-07-02 | 1995-01-24 | Tokuyama Corp | 免疫学的凝集反応試薬 |
JPH0875746A (ja) * | 1994-09-02 | 1996-03-22 | Tokuyama Corp | 免疫学的凝集反応用担体粒子の凝集特性評価方法 |
JP3095541B2 (ja) | 1992-09-08 | 2000-10-03 | 株式会社トクヤマ | 免疫学的凝集反応試薬の製造方法 |
JP2005351643A (ja) | 2004-06-08 | 2005-12-22 | Dai Ichi Pure Chem Co Ltd | 免疫学的測定試薬 |
WO2007063616A1 (ja) * | 2005-11-30 | 2007-06-07 | Nihon University | 超高感度c-反応性タンパク質測定試薬及び測定方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2525486B2 (ja) | 1989-09-07 | 1996-08-21 | 富士写真フイルム株式会社 | 写真焼付方法 |
-
2010
- 2010-03-04 ES ES10748806.6T patent/ES2440326T3/es active Active
- 2010-03-04 EP EP10748806.6A patent/EP2418486B1/en active Active
- 2010-03-04 WO PCT/JP2010/053541 patent/WO2010101213A1/ja active Application Filing
- 2010-03-04 DK DK10748806.6T patent/DK2418486T3/da active
- 2010-03-04 CN CN201080010075.8A patent/CN102341707B/zh active Active
- 2010-03-04 KR KR1020117023250A patent/KR101628221B1/ko active IP Right Grant
- 2010-03-04 JP JP2011502797A patent/JP5706315B2/ja active Active
- 2010-03-04 US US13/254,765 patent/US9250235B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57182168A (en) | 1981-05-02 | 1982-11-09 | Mitsubishi Chem Ind Ltd | Immunochemical reagent |
JPH06167495A (ja) * | 1992-07-14 | 1994-06-14 | S R L:Kk | 凝集イムノアッセイ法 |
JP3095541B2 (ja) | 1992-09-08 | 2000-10-03 | 株式会社トクヤマ | 免疫学的凝集反応試薬の製造方法 |
JPH0720129A (ja) * | 1993-07-02 | 1995-01-24 | Tokuyama Corp | 免疫学的凝集反応試薬 |
JPH0875746A (ja) * | 1994-09-02 | 1996-03-22 | Tokuyama Corp | 免疫学的凝集反応用担体粒子の凝集特性評価方法 |
JP2005351643A (ja) | 2004-06-08 | 2005-12-22 | Dai Ichi Pure Chem Co Ltd | 免疫学的測定試薬 |
WO2007063616A1 (ja) * | 2005-11-30 | 2007-06-07 | Nihon University | 超高感度c-反応性タンパク質測定試薬及び測定方法 |
Non-Patent Citations (2)
Title |
---|
J.BIOMATER.SCI.POLYMER EDN, vol. 10, no. 11, 1999, pages 1093 - 1105 |
See also references of EP2418486A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013090636A1 (en) * | 2011-12-13 | 2013-06-20 | Baxter International Inc. | Measurement of autoantibodies at low conductivity conditions with increased sensitivity |
US9075069B2 (en) | 2011-12-13 | 2015-07-07 | Baxter International Inc. | Measurement of autoantibodies at low conductivity with increased sensitivity |
Also Published As
Publication number | Publication date |
---|---|
US20120107957A1 (en) | 2012-05-03 |
DK2418486T3 (da) | 2013-12-16 |
ES2440326T3 (es) | 2014-01-28 |
KR20110134445A (ko) | 2011-12-14 |
JP5706315B2 (ja) | 2015-04-22 |
JPWO2010101213A1 (ja) | 2012-09-10 |
EP2418486A4 (en) | 2012-10-31 |
EP2418486A1 (en) | 2012-02-15 |
EP2418486B1 (en) | 2013-11-06 |
CN102341707B (zh) | 2014-05-07 |
KR101628221B1 (ko) | 2016-06-08 |
US9250235B2 (en) | 2016-02-02 |
CN102341707A (zh) | 2012-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012018057A1 (ja) | イムノクロマトグラフィー用試薬組成物およびそれを用いた測定方法 | |
JP5706315B2 (ja) | 検査試薬及びそれを用いた被検試料中の被測定物の測定方法 | |
EP2799870B1 (en) | Method for reducing adsorption of bubbles | |
WO2020045524A1 (ja) | クロマトグラフキットおよびクロマトグラフ方法 | |
EP4249508A1 (en) | Sars-cov-2 detection kit and sars-cov-2 detection method | |
JP2007315883A (ja) | 免疫測定用ラテックス組成物 | |
EP2833141B1 (en) | Immunological analysis method | |
JP6729995B2 (ja) | 免疫分析方法及び試薬 | |
WO2019026569A1 (ja) | 不溶性担体粒子を含有する免疫測定試薬の劣化防止手段 | |
JP2006071297A (ja) | 抗原の測定方法及びそのための試薬 | |
JP6919499B2 (ja) | 不溶性担体粒子を含有する免疫測定試薬の劣化防止手段 | |
WO2017090103A1 (ja) | 免疫分析方法及び試薬キット | |
JP2004191332A (ja) | 免疫学的分析試薬及び免疫学的分析方法 | |
JP2007033378A (ja) | 標識試薬の感度調整方法 | |
JP4452324B2 (ja) | 精製血清アルブミン及び免疫学的測定方法 | |
JP4514233B2 (ja) | イムノクロマトグラフィー用試験キット | |
JP7257556B2 (ja) | イムノクロマトグラフィー | |
WO2022265105A1 (ja) | イムノクロマト試験片およびイムノクロマトキット | |
WO2021153127A1 (ja) | 免疫検査方法 | |
JP2019101011A (ja) | 感作された不溶性担体粒子を含有する免疫測定試薬の劣化防止手段 | |
JPH08105897A (ja) | 免疫測定法 | |
WO2009123061A1 (ja) | 精製血清アルブミン及び免疫学的測定方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080010075.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10748806 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011502797 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20117023250 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010748806 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13254765 Country of ref document: US |